[go: up one dir, main page]

WO2016126115A3 - Pharmaceutical composition comprising pitavastatin or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof - Google Patents

Pharmaceutical composition comprising pitavastatin or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof Download PDF

Info

Publication number
WO2016126115A3
WO2016126115A3 PCT/KR2016/001212 KR2016001212W WO2016126115A3 WO 2016126115 A3 WO2016126115 A3 WO 2016126115A3 KR 2016001212 W KR2016001212 W KR 2016001212W WO 2016126115 A3 WO2016126115 A3 WO 2016126115A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
acceptable salt
pitavastatin
valsartan
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2016/001212
Other languages
French (fr)
Other versions
WO2016126115A2 (en
Inventor
Min-Seok Choi
Yun-Sik UM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
JW Pharmaceutical Corp
Original Assignee
Kowa Co Ltd
JW Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd, JW Pharmaceutical Corp filed Critical Kowa Co Ltd
Publication of WO2016126115A2 publication Critical patent/WO2016126115A2/en
Publication of WO2016126115A3 publication Critical patent/WO2016126115A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)

Abstract

Disclosed is a composite composition comprising pitavastatin or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof and the composite pharmaceutical composition is more stable than simple formulations in combination, and is economically beneficial compared to a controlled-release formulation.
PCT/KR2016/001212 2015-02-04 2016-02-04 Pharmaceutical composition comprising pitavastatin or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof Ceased WO2016126115A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150017261A KR20160095826A (en) 2015-02-04 2015-02-04 Pharmaceutical composition comprising pitavastatin or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof
KR10-2015-0017261 2015-02-04

Publications (2)

Publication Number Publication Date
WO2016126115A2 WO2016126115A2 (en) 2016-08-11
WO2016126115A3 true WO2016126115A3 (en) 2016-10-06

Family

ID=56564857

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/001212 Ceased WO2016126115A2 (en) 2015-02-04 2016-02-04 Pharmaceutical composition comprising pitavastatin or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof

Country Status (3)

Country Link
KR (1) KR20160095826A (en)
TW (1) TW201636022A (en)
WO (1) WO2016126115A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102406616B1 (en) * 2019-12-19 2022-06-10 대원제약주식회사 A pharmaceutical composition comprising angiotensin receptor blocker and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080039303A (en) * 2006-10-30 2008-05-07 한올제약주식회사 Combination composition of controlled release angiotensin-II-receptor blocker and HMV-COA reductase inhibitor
KR20090114190A (en) * 2008-04-29 2009-11-03 한올제약주식회사 Combination composition of controlled release of HMV-CoA reductase inhibitor and angiotensin-II-receptor blocker
KR20140111982A (en) * 2013-03-12 2014-09-22 주식회사 엘지생명과학 Complex formulation comprising valsartan and rosuvastatin calcium and method for the preparation thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080039303A (en) * 2006-10-30 2008-05-07 한올제약주식회사 Combination composition of controlled release angiotensin-II-receptor blocker and HMV-COA reductase inhibitor
KR20090114190A (en) * 2008-04-29 2009-11-03 한올제약주식회사 Combination composition of controlled release of HMV-CoA reductase inhibitor and angiotensin-II-receptor blocker
KR20140111982A (en) * 2013-03-12 2014-09-22 주식회사 엘지생명과학 Complex formulation comprising valsartan and rosuvastatin calcium and method for the preparation thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IMANISHI, T. ET AL.: "Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits.", HYPERTENSION RESEARCH, vol. 31, no. 6, 2008, pages 1199 - 1208, XP055317359 *
JUNG, J. A. ET AL.: "Pharmacokinetic interaction between pitavastatin and valsartan: a randomized, open-labeled crossover study in healthy male Korean volunteers.", CLINICAL THERAPEUTICS, vol. 34, no. 4, 2012, pages 958 - 965, XP028406663 *

Also Published As

Publication number Publication date
WO2016126115A2 (en) 2016-08-11
KR20160095826A (en) 2016-08-12
TW201636022A (en) 2016-10-16

Similar Documents

Publication Publication Date Title
CA2956871C (en) Compounds active towards bromodomains
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
WO2015165413A8 (en) New stable antibody-drug conjugate, preparation method therefor, and use thereof
WO2016131067A3 (en) Pharmaceutical compositions comprising meloxicam
CA2894891A1 (en) Boronic acid derivatives and therapeutic uses thereof
WO2014180889A8 (en) Methods and compositions for the treatment of cancer
EP3412292B8 (en) Use of methoxatin, derivative and/or salt thereof in sjogren's syndrome and pharmaceutical composition
MX2016003754A (en) A stable pharmaceutical composition containing amlodipine and valsartan.
WO2011104652A3 (en) Veterinary compositions
HK1254343A1 (en) Pharmaceutical formulations
WO2015056094A3 (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
PH12016500865A1 (en) Composite formulation comprising tadalafil and amlodipine
WO2014114255A3 (en) Positioning, quick-release bioadhesion agent and use
EP3162804A8 (en) New benzodiazepine derivative and use thereof
MY191219A (en) Therapeutic agent for fibrosis
EP4342461A3 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
HK1214519A1 (en) Dual use oral pharmaceutical composition tablets of sulfate saltes and methods of use thereof
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
MX360047B (en) Solid unit with high fexofenadine content and process for the preparation thereof.
CA3011003A1 (en) Bacterial ghosts for the treatment of cancer
WO2014027979A3 (en) Tablet formulations comprising tadalafil and dapoxetine
MX2019001771A (en) Solid pharmaceutical composition comprising amorphous sofosbuvir.
WO2016126115A3 (en) Pharmaceutical composition comprising pitavastatin or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof
WO2017064652A3 (en) Low dose oral dipyridamole compositions and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16746856

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16746856

Country of ref document: EP

Kind code of ref document: A2